VistaGen Hopes To Bounce Back With Spray-Based Depression Drug

Good News After Two Failures

NASDAQ-listed company’s shares were reduced to penny stock after trial failures in 2019, but nasal spray PH10 offers glimmer of hope.

VistaGen

More from Business

More from Scrip